-
公开(公告)号：US20220228222A1
公开(公告)日：2022-07-21
申请号：US17609517
申请日：2020-05-08
申请人： Christopher Goodnow , Megan Barnet , Katherine Jackson , Jonathan Cebon , Andreas Behren , Garvan Institute of Medical Research , Olivia Newton-John Cancer Research Institute
IPC分类号： C12Q1/6886 , A61P35/04 , C07K16/28 , C07K16/18 , A61P35/00
摘要： The present disclosure relates to predicting a patient's response to cancer therapy based on the presence or absence of loss of function NOD-2 variants, as well as methods of treating cancer comprising inhibiting NOD-2 function.
-
公开(公告)号：US20210324035A1
公开(公告)日：2021-10-21
申请号：US17273192
申请日：2019-09-04
申请人： The Regents of the University of California , California Institute of Technology , The Olivia Newton-John Cancer Research Institute
发明人： Owen N. Witte , Jami McLaughlin Witte , Antoni Ribas , Lili Yang , Michael T. Bethune , Jonathan Cebon , Katherine Woods , Ashley J. Knights , David Baltimore
IPC分类号： C07K14/725 , A61K35/17 , C12N15/86 , C12N5/0783 , A61P35/00
摘要： Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.
-
3.发明授权Method for determining presence of cancer in a sample by assaying for expression of ECSA/DPPA-2 nucleotide sequences 失效通过测定ECSA / DPPA-2核苷酸序列的表达来确定样品中癌症存在的方法公开(公告)号：US08354243B2
公开(公告)日：2013-01-15
申请号：US12310802
申请日：2007-10-02
IPC分类号： G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/16
摘要： The invention relates to the discovery of known molecule “DPPA-2” and a so-called “cancer-testis antigen.” DPPA-2 is also a possible cancer stem cell marker. One can determine presence of cancer by assaying for the molecule, and also prevent or treat cancer via administration of the molecule.
摘要翻译： 本发明涉及已知的分子DPPA-2和所谓的癌 - 睾丸抗原的发现。 DPPA-2也是可能的癌症干细胞标志物。 可以通过分析分子来确定癌症的存在，还可以通过施用分子来预防或治疗癌症。
-
4.发明申请METHOD FOR DETERMINING PRESENCE OF CANCER IN A SAMPLE BY ASSAYING FOR EXPRESSION OF DPPA-2 NUCLEOTIDE SEQUENCES 失效通过测定DPPA-2核苷酸序列表达来确定样品中存在癌症的方法公开(公告)号：US20100210522A1
公开(公告)日：2010-08-19
申请号：US12310802
申请日：2007-10-02
IPC分类号： A61K38/16 , C12Q1/68 , A61K31/7088 , A61P35/04
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/16
摘要： The invention relates to the discovery of known molecule “ESCA/DPPA-2” and a so-called “cancer-testis antigen.” ESCA/DPPA-2 is also a possible cancer stem cell marker. One can determine presence of cancer by assaying for the molecule, and also prevent or treat cancer via administration of the molecule.
摘要翻译： 本发明涉及已知分子“ESCA / DPPA-2”和所谓的“癌 - 睾丸抗原”的发现.ESCA / DPPA-2也是可能的癌症干细胞标记。 可以通过分析分子来确定癌症的存在，还可以通过施用分子来预防或治疗癌症。
-
公开(公告)号：US20170107583A1
公开(公告)日：2017-04-20
申请号：US15391293
申请日：2016-12-27
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G06F19/00 , G16H50/30
摘要： The invention relates to prognostic markers and prognostic signatures, and compositions and methods for determining the prognosis of cancer in a patient, particularly for melanoma. Specifically, the invention relates to the use of genetic and protein markers for the prediction of the risk of progression of a cancer, such as melanoma, based on markers and signatures of markers. In various aspects, the invention provides methods, compositions, kits, and devices based on prognostic cancer markers, specifically melanoma prognostic markers, to aid in the prognosis and treatment of cancer.
-
公开(公告)号：US08822149B2
公开(公告)日：2014-09-02
申请号：US12592385
申请日：2009-11-23
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G06F19/00 , G16H50/30
摘要： The invention relates to prognostic markers and prognostic signatures, and compositions and methods for determining the prognosis of cancer in a patient, particularly for melanoma. Specifically, the invention relates to the use of genetic and protein markers for the prediction of the risk of progression of a cancer, such as melanoma, based on markers and signatures of markers. In various aspects, the invention provides methods, compositions, kits, and devices based on prognostic cancer markers, specifically melanoma prognostic markers, to aid in the prognosis and treatment of cancer.
摘要翻译： 本发明涉及预后标志物和预后特征，以及用于确定患者中癌症预后的组合物和方法，特别是对于黑素瘤。 具体而言，本发明涉及遗传和蛋白质标记物用于基于标记物和标记物的标记来预测癌症进展风险（例如黑素瘤）的用途。 在各个方面，本发明提供了基于预后癌症标志物，特别是黑素瘤预后标志物的方法，组合物，试剂盒和装置，以帮助癌症的预后和治疗。
-
公开(公告)号：US20100136553A1
公开(公告)日：2010-06-03
申请号：US12592385
申请日：2009-11-23
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G06F19/00 , G16H50/30
摘要： The invention relates to prognostic markers and prognostic signatures, and compositions and methods for determining the prognosis of cancer in a patient, particularly for melanoma. Specifically, the invention relates to the use of genetic and protein markers for the prediction of the risk of progression of a cancer, such as melanoma, based on markers and signatures of markers. In various aspects, the invention provides methods, compositions, kits, and devices based on prognostic cancer markers, specifically melanoma prognostic markers, to aid in the prognosis and treatment of cancer.
摘要翻译： 本发明涉及预后标志物和预后特征，以及用于确定患者中癌症预后的组合物和方法，特别是对于黑素瘤。 具体而言，本发明涉及遗传和蛋白质标记物用于基于标记物和标记物的标记来预测癌症进展风险（例如黑素瘤）的用途。 在各个方面，本发明提供了基于预后癌症标志物，特别是黑素瘤预后标志物的方法，组合物，试剂盒和装置，以帮助癌症的预后和治疗。
-
公开(公告)号：US10266902B2
公开(公告)日：2019-04-23
申请号：US15391293
申请日：2016-12-27
IPC分类号： C12Q1/68 , G06F19/00 , C12Q1/6886 , G16H50/30
摘要： The invention relates to prognostic markers and prognostic signatures, and compositions and methods for determining the prognosis of cancer in a patient, particularly for melanoma. Specifically, the invention relates to the use of genetic and protein markers for the prediction of the risk of progression of a cancer, such as melanoma, based on markers and signatures of markers. In various aspects, the invention provides methods, compositions, kits, and devices based on prognostic cancer markers, specifically melanoma prognostic markers, to aid in the prognosis and treatment of cancer.
-
公开(公告)号：US20120171232A1
公开(公告)日：2012-07-05
申请号：US13111381
申请日：2011-05-19
申请人： Jonathan Cebon , Ian Davis , Weisan Chen , Simon Green
发明人： Jonathan Cebon , Ian Davis , Weisan Chen , Simon Green
CPC分类号： A61K39/0011 , A61K9/0021 , A61K2039/54 , A61K2039/545 , A61K2039/55577 , A61K2039/57 , A61K2039/572 , G01N33/57492 , G01N2333/70514 , G01N2333/70517
摘要： The invention relates to the discovery that administration of NY-ESO-1 protein, in combination with a saponin based adjuvant leads to an unexpectedly strong immune response against NY-ESO-1 expressing cells. Preferably, the combination is administered intramuscularly.
摘要翻译： 本发明涉及以下发现：NY-ESO-1蛋白与基于皂苷的佐剂的组合导致对于表达NY-ESO-1的细胞的意想不到的强的免疫应答。 优选地，肌内注射组合。
-
10.发明申请METHOD FOR MODIFYING CELLUAR IMMUNE RESONSE BY MODULATING ACTIVIN ACTIVITY 审中-公开通过调节活性活性来修饰细胞免疫调节的方法公开(公告)号：US20100279409A1
公开(公告)日：2010-11-04
申请号：US12733670
申请日：2008-09-11
IPC分类号： C12N5/0783
CPC分类号： C12N5/0639 , A61K39/39 , C12N2501/16
摘要： The invention relates to methods for modifying a cellular response, such as a CD8+ T cell or NK cell response, by adding an activin modulator in an amount sufficient to modulate activin production. By modulating this production, the cellular response is itself modulated.
摘要翻译： 本发明涉及通过加入足以调节激活素产生量的激活素调节剂来修饰细胞应答如CD8 + T细胞或NK细胞应答的方法。 通过调节这种生产，细胞反应本身被调节。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.036 秒)
